Calza Leonardo, Borderi Marco, Colangeli Vincenzo, Esposito Fabio, Giglia Maddalena, Bon Isabella, Re Maria Carla
Unit of Infectious Diseases and Department of Medical and Surgical Sciences, "Alma Mater Studiorum" University of Bologna, S. Orsola Hospital, Bologna, Italy.
Unit of Microbiology, Department of Medical and Surgical Sciences, "Alma Mater Studiorum" University of Bologna, S. Orsola Hospital, Bologna, Italy.
AIDS Res Hum Retroviruses. 2021 Jan;37(1):11-15. doi: 10.1089/AID.2020.0167. Epub 2020 Oct 20.
A significant weight gain has been reported in HIV-infected patients starting combination antiretroviral therapy (cART) including integrase strand transfer inhibitors, but clinical data about changes in body fat mass are still lacking. An observational retrospective analysis was made to evaluate changes in body fat mass and weight in 39 cART-naive patients initiating a first antiretroviral treatment, including tenofovir disoproxil fumarate/emtricitabine plus raltegravir (RAL) or darunavir/ritonavir (DRV/r), and who had a follow-up of at least 12 months and a whole-body dual-energy X-ray absorptiometry performed at baseline and after 12 months. After 12 months, changes in weight and total fat mass were comparable and statistically not significant in both groups. The median increase [interquartile range (IQR)] in weight was +2.02 kg (+1.19, +2.95; = .378) in RAL group, and +1.71 kg (+0.89, +2.54; = .449) in DRV/r group. The median increase in body fat mass (IQR) was +1.27 kg (+1.09, +1.43; = .278) in RAL group, and +1.04 kg (+0.89, +1.22; = .781) in DRV/r group. In conclusion, in our study, an initial regimen including RAL plus tenofovir/emtricitabine after 12 months led to a small and nonsignificant increase in weight and body fat mass, and changes were comparable with a DRV/r-based initial regimen.
据报道，开始接受包括整合酶链转移抑制剂在内的联合抗逆转录病毒疗法（cART）的HIV感染患者体重显著增加，但关于体脂量变化的临床数据仍然缺乏。我们进行了一项观察性回顾性分析，以评估39例初治cART患者在开始首次抗逆转录病毒治疗（包括替诺福韦酯/恩曲他滨加拉替拉韦（RAL）或达芦那韦/利托那韦（DRV/r））后的体脂量和体重变化，这些患者至少随访了12个月，并在基线和12个月后进行了全身双能X线吸收测定。12个月后，两组的体重和总脂肪量变化相当，且无统计学意义。RAL组体重的中位数增加[四分位间距（IQR）]为+2.02 kg（+1.19，+2.95；P = 0.378），DRV/r组为+1.71 kg（+0.89，+2.54；P = 0.449）。RAL组体脂量的中位数增加（IQR）为+1.27 kg（+1.09，+1.43；P = 0.278），DRV/r组为+1.04 kg（+0.89，+1.22；P = 0.781）。总之，在我们的研究中，12个月后包括RAL加替诺福韦/恩曲他滨的初始治疗方案导致体重和体脂量小幅增加且无统计学意义，且变化与基于DRV/r的初始治疗方案相当。
